DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Arrowhead Research Corporation (ARWR)
« Back to company indexARWR Chatter Timeline
Stock Ticker for ARWR
Most Active Tweeters for ARWR
| User | Tweets |
|---|---|
| @battagliame30 | 33 |
| @fpscod9 | 18 |
| @pt117cool | 16 |
| @truthtracer | 15 |
| @joetrader87 | 13 |
Recent Tweets for ARWR
 |
@fpscod9 @biotech_batman @BikeRieder $ARWR Hey MD PhD Batman Pajama Boy, You need an internship from NatureDotcom, maybe y… https://t.co/U7RuJCdHT5 October 21st 2019, 6:10pm |
|
@fpscod9 @Jon12508683 $ARWR Please post/link your valuation model, so we all can discuss it as compare to model developed by @BioBoyScout October 21st 2019, 5:10pm |
 |
@stockmktgenius $ARWR Arrowhead Pharmaceuticals Top stock up 241% from low. Close: 36.50 VolvsAvg: 0.81 Liq: $40M https://t.co/AeDFICx3eC October 21st 2019, 5:10pm |
 |
@YuZhu4 RT @BikeRieder: $ARWR AD, Bruce Given in my words: RNAi is wonderful because mother nature has done the experiment. It's a natural occurrin… October 21st 2019, 1:10pm |
 |
@Steve_382 $ARWR How accurate is this number from the Nature article? Johnson & Johnson in New Brunswick, New Jersey, purch… https://t.co/lDe4L45CyS October 21st 2019, 1:10pm |
 |
@dispatchtribune Arrowhead Pharmaceuticals’ $ARWR Overweight Rating Reiterated at Piper Jaffray Companies https://t.co/3oxNh3tdpv October 21st 2019, 10:10am |
|
@fpscod9 @BikeRieder $ARWR Haha, I said the same few weeks ago in regards to RNAi as the natural mechanism of "interference"… https://t.co/RcnbZpsdTq October 21st 2019, 7:10am |
 |
@BikeRieder $ARWR AD, Bruce Given in my words: RNAi is wonderful because mother nature has done the experiment. It's a natural… https://t.co/ObUiihy17V October 21st 2019, 7:10am |
 |
@Quantumup1 $ARWR PT raised to $54, Overweight rating reiterated at Piper Jaffray https://t.co/9zusqbA1jT October 21st 2019, 6:10am |
 |
@OlympiaReport FY2019 Earnings Estimate for Arrowhead Pharmaceuticals Inc $ARWR Issued By Cantor Fitzgerald https://t.co/QuhT9h9bm6 October 21st 2019, 2:10am |
 |
@WeekHerald FY2019 Earnings Estimate for Arrowhead Pharmaceuticals Inc $ARWR Issued By Cantor Fitzgerald https://t.co/kwHJFqtzcV October 21st 2019, 2:10am |
 |
@RatingsNetwork Cantor Fitzgerald Sets Arrowhead Pharmaceuticals FY2019 Earnings Estimates at $0.67 EPS. https://t.co/8cUeeNvTMi $ARWR #ARWR October 21st 2019, 2:10am |
 |
@JanniMore RT @AjTrader7: IN FRIDAY'S LIVE TRADING WEBINAR RE-CAP FOR 10/18/2019 $ARWR THIS WAS A CRAMER PUMP ON THURSDAY'S SHOW, NO OTHER REASON FOR… October 21st 2019, 2:10am |
 |
@jerchess $ARWR Dr J, Spike & friends chart and discuss this name https://t.co/hbCRQlMyKg October 21st 2019, 1:10am |
|
@jerchess @shaab5 probably a small pullback then wait for rsi to cross 80. That’s one way to play it. Let me ask u same question about $ARWR October 21st 2019, 1:10am |
|
@WeekHerald Arrowhead Pharmaceuticals $ARWR Earns Overweight Rating from Piper Jaffray Companies https://t.co/xvCK5SWmL5 October 20th 2019, 9:10pm |
|
@OlympiaReport Arrowhead Pharmaceuticals $ARWR Earns Overweight Rating from Piper Jaffray Companies https://t.co/gE5D7WZqhu October 20th 2019, 9:10pm |
 |
@AmericanBanking Arrowhead Pharmaceuticals’ $ARWR “Overweight” Rating Reiterated at Piper Jaffray Companies https://t.co/fxwSCVHmqs #stocks October 20th 2019, 9:10pm |
 |
@biotechw2019 $ARWR still grinding a higher high. https://t.co/kunuqiJSlS October 20th 2019, 7:10pm |
 |
@iknowtybo High-volume breakouts expected for $ARWR this week. October 20th 2019, 5:10pm |
 |
@battagliame30 @truthtracer @joetrader87 New $JNJ + $ARWR 12-dose combo trial is all about HBV-e-negs patients(virologically suppr… https://t.co/n14XNcQiBf October 20th 2019, 3:10pm |
|
@battagliame30 @truthtracer @joetrader87 If FCs are on there way from e+ patients in $JNJ + $ARWR cohort-12 trial, we might see a… https://t.co/BVbNFtYK22 October 20th 2019, 3:10pm |
 |
@AjTrader7 IN FRIDAY'S LIVE TRADING WEBINAR RE-CAP FOR 10/18/2019 $ARWR THIS WAS A CRAMER PUMP ON THURSDAY'S SHOW, NO OTHER R… https://t.co/65TfM3qpBN October 20th 2019, 1:10pm |
|
@BikeRieder @joetrader87 @truthtracer $ARWR got $25 mil milestone payments for first triple combo trial. October 20th 2019, 4:10am |
 |
@ConsumerFeed Arrowhead Pharmaceuticals’ $ARWR Neutral Rating Reaffirmed at Cantor Fitzgerald https://t.co/tLFRIfYwGu October 20th 2019, 1:10am |
 |
@truthtracer @joetrader87 $ARWR Groups that are bottom line oriented, save, extend & create better quality of life~Safely. That’… https://t.co/CJerkJibpM October 20th 2019, 12:10am |
|
@truthtracer @joetrader87 $ARWR Logically, FC s are the goal which has already been implied. However if the FDA clearly sees a p… https://t.co/Jm4Sf9newA October 19th 2019, 11:10pm |
|
@truthtracer @joetrader87 $ARWR Specifics would logically inhabit that negotiable space between the FDA & Janssen via agreed upo… https://t.co/kDPIQY0Iqi October 19th 2019, 11:10pm |
|
@battagliame30 @IonisDisrupts @fpscod9 $ARWR CEO might be more prone to being “HYPERSPECIFIC,” at least from y’day’s Analyst’s Day… https://t.co/wkQh3IRXMp October 19th 2019, 11:10pm |
|
@fpscod9 @BioBoyScout $ARWR Another CA genius move, ie JNJ3989 partnership with $JNJ considering all the combos needed plus… https://t.co/TXlQrN2aMx October 19th 2019, 11:10pm |
|
@battagliame30 @BioBoyScout 12 months dosing of $JNJ + $ARWR HBV-combo should provide substantial safety data compared to 3 months dosing, too. October 19th 2019, 9:10pm |
|
@truthtracer @joetrader87 $ARWR As you might suppose, the interpretation of what constitutes a surrogate endpoint is FDA territo… https://t.co/m2WBlsNVjR October 19th 2019, 8:10pm |
|
@battagliame30 RT @truthtracer: $ARWR It’s would seem a certainty that accelerated approval is on $JNJ (Janssen’s) radar. https://t.co/hQbkRtuagy… October 19th 2019, 7:10pm |
|
@battagliame30 @BioBoyScout No doubt we see FCs. Maybe some patients will not need all 12 doses of HBV-combo drug. $JNJ + $ARWR. Great news. October 19th 2019, 7:10pm |
|
@battagliame30 RT @BioBoyScout: $ARWR big win with the new 3x combo clinical trial for their licensed HBV drug with $JNJ. Very aggressive 12 monthly doses… October 19th 2019, 7:10pm |
|
@battagliame30 @BioBoyScout 12 month (assuming 12 doses) should allow $JNJ + $ARWR to chose when to stop treatment. Assuming it wi… https://t.co/p0fB35Dg81 October 19th 2019, 7:10pm |
|
@BikeRieder @truthtracer $ARWR This new trial could trigger a new milestone payment when first patients are dosed! 25-50 mil ??? October 19th 2019, 6:10pm |
|
@truthtracer RT @PersimmonTI: $ARWR $MRK Arrowhead, Merck, HIF-2 & the Nobel Prize in Medicine: https://t.co/0oBp3iDFHb October 19th 2019, 5:10pm |
|
@truthtracer $ARWR It’s would seem a certainty that accelerated approval is on $JNJ (Janssen’s) radar. https://t.co/hQbkRtuagy… https://t.co/AXOQpD3sFV October 19th 2019, 3:10pm |
 |
@BioBoyScout $ARWR big win with the new 3x combo clinical trial for their licensed HBV drug with $JNJ. Very aggressive 12 monthl… https://t.co/2xzsMb6N0O October 19th 2019, 3:10pm |
|
@truthtracer @ModDarvasBox Post CNBC’s (Mad Money) Jim Cramer’s $ARWR interview w/CEO Chris Anzalone, essentially highlighting t… https://t.co/NceWb6saPx October 19th 2019, 2:10pm |
 |
@dailypoliticaln Arrowhead Pharmaceuticals $ARWR Given Neutral Rating at Cantor Fitzgerald https://t.co/HkrvUT8hDa October 19th 2019, 2:10pm |
 |
@TickerReport Arrowhead Pharmaceuticals $ARWR Given Neutral Rating at Cantor Fitzgerald https://t.co/HrSoHKYoCM October 19th 2019, 2:10pm |
 |
@IonisDisrupts @battagliame30 @fpscod9 $ions Lica results are much cleaner. No fls for one, far fewer overall AEs . $Arwr CEO see… https://t.co/iYtyCh6CLJ October 19th 2019, 11:10am |
 |
@TheSliv RT @btendent: Me thinks, $ARWR is building generational wealth for their shareholders. October 19th 2019, 11:10am |
|
@btendent Me thinks, $ARWR is building generational wealth for their shareholders. October 19th 2019, 10:10am |
 |
@stocknewstimes Arrowhead Pharmaceuticals $ARWR Reaches New 52-Week High at $37.28 https://t.co/MWqjo09SKW October 19th 2019, 9:10am |
 |
@TranscriptDaily Arrowhead Pharmaceuticals $ARWR Sets New 12-Month High at $37.28 https://t.co/D6KG7xxKtR October 19th 2019, 9:10am |
|
@AmericanBanking Cantor Fitzgerald Reiterates Neutral Rating for Arrowhead Pharmaceuticals $ARWR https://t.co/3ZRGUoBj9A #stocks October 19th 2019, 8:10am |
 |
@ZolmaxNews Arrowhead Pharmaceuticals’ $ARWR Neutral Rating Reiterated at Cantor Fitzgerald https://t.co/a0JqpDbb45 October 19th 2019, 7:10am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.